Literature DB >> 33407684

Quality of life in Italian patients with Multiple endocrine neoplasia type 1 (MEN 1): results of an extensive survey.

Francesca Giusti1, Federica Cioppi1, Caterina Fossi1, Francesca Marini1, Laura Masi1, Francesco Tonelli1, Maria Luisa Brandi2.   

Abstract

BACKGROUND: MEN1 is a complex, rare, syndrome inherited in an autosomal dominant tract and characterized by the development of multiple neuroendocrine tumors, requiring lifelong surveillance and multiple medical and surgical therapies throughout the patient's life. For all these reasons, a diagnosis of MEN1 can be a psychological shock for the patient, as well as his/her relatives, more so than the diagnosis of a single tumor. In the last two decades, clinicians have started to consider the emotional, psychological, relational, and social aspects of their patients' lives. The data collected in the present analyses highlight the unique features of MEN1 syndrome, and aim to evaluate the Quality of Life in the patients and their relatives. In this study, a comprehensive survey of various aspects of Health-Related Quality of Life was performed in a large series of Italian MEN1 patients, by administering five of the most common targeted questionnaires.
RESULTS: The results of the study showed that our patients, despite having a complex multi-tumor syndrome, were moderately optimistic (50%), and this corresponds with a normal Quality of Life. This positive response is strictly correlated with the fact that the patients are cared for at a dedicated Referral Center, receiving personalized care and constant follow-up, which gives them reassurance regarding the high quality of management of the disorder.
CONCLUSIONS: The possibility of having access to a clinical Referral Center for their complex rare disease, together with the support of a dedicated patient association, has been demonstrated to be the ideal model for the management of post-diagnosis shock, and contributes to the preservation of a good Health-Related Quality of Life for MEN1 patients.

Entities:  

Keywords:  HADS; IES-R; LOT-R; Multiple endocrine neoplasia type 1; Neuroendocrine tumors; Quality of life; SF-36

Mesh:

Year:  2021        PMID: 33407684      PMCID: PMC7788910          DOI: 10.1186/s13023-020-01650-y

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


  14 in total

Review 1.  Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1).

Authors:  Rajesh V Thakker; Paul J Newey; Gerard V Walls; John Bilezikian; Henning Dralle; Peter R Ebeling; Shlomo Melmed; Akihiro Sakurai; Francesco Tonelli; Maria Luisa Brandi
Journal:  J Clin Endocrinol Metab       Date:  2012-06-20       Impact factor: 5.958

Review 2.  The management of psychological issues in oncology.

Authors:  Daniel C McFarland; Jimmie C Holland
Journal:  Clin Adv Hematol Oncol       Date:  2016-12

3.  The Italian SF-36 Health Survey: translation, validation and norming.

Authors:  G Apolone; P Mosconi
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

4.  Comparison of Rasch and summated rating scales constructed from SF-36 physical functioning items in seven countries: results from the IQOLA Project. International Quality of Life Assessment.

Authors:  A E Raczek; J E Ware; J B Bjorner; B Gandek; S M Haley; N K Aaronson; G Apolone; P Bech; J E Brazier; M Bullinger; M Sullivan
Journal:  J Clin Epidemiol       Date:  1998-11       Impact factor: 6.437

5.  Health-related quality of life in MEN1 patients compared with other chronic conditions and the United States general population.

Authors:  Benjamin J Peipert; Sneha Goswami; Susan E Yount; Cord Sturgeon
Journal:  Surgery       Date:  2017-11-08       Impact factor: 3.982

6.  The World Health Organization Quality of Life assessment (WHOQOL): position paper from the World Health Organization.

Authors: 
Journal:  Soc Sci Med       Date:  1995-11       Impact factor: 4.634

7.  Quality of life in patients with multiple endocrine neoplasia type 1 (MEN 1).

Authors:  G Berglund; A Lidén; M G Hansson; K Oberg; P O Sjöden; K Nordin
Journal:  Fam Cancer       Date:  2003       Impact factor: 2.375

8.  The hospital anxiety and depression scale.

Authors:  A S Zigmond; R P Snaith
Journal:  Acta Psychiatr Scand       Date:  1983-06       Impact factor: 6.392

9.  Psychometric properties of the Impact of Event Scale - Revised.

Authors:  Mark Creamer; Richard Bell; Salvina Failla
Journal:  Behav Res Ther       Date:  2003-12

10.  Optimism and pessimism in the general population: Psychometric properties of the Life Orientation Test (LOT-R).

Authors:  Andreas Hinz; Christian Sander; Heide Glaesmer; Elmar Brähler; Markus Zenger; Anja Hilbert; Rüya-Daniela Kocalevent
Journal:  Int J Clin Health Psychol       Date:  2017-03-31
View more
  3 in total

Review 1.  Valuing the "Burden" and Impact of Rare Diseases: A Scoping Review.

Authors:  Julien Delaye; Pasquale Cacciatore; Anna Kole
Journal:  Front Pharmacol       Date:  2022-06-08       Impact factor: 5.988

2.  Social and Family Challenges of Having a Child Diagnosed with Phelan-McDermid Syndrome: A Qualitative Study of Parents' Experiences.

Authors:  Cristina García-Bravo; Domingo Palacios-Ceña; Sara García-Bravo; Jorge Pérez-Corrales; Marta Pérez-de-Heredia-Torres; Rosa Mª Martínez-Piédrola
Journal:  Int J Environ Res Public Health       Date:  2022-08-24       Impact factor: 4.614

Review 3.  Update on the clinical management of multiple endocrine neoplasia type 1.

Authors:  Carolina R C Pieterman; Gerlof D Valk
Journal:  Clin Endocrinol (Oxf)       Date:  2022-04-01       Impact factor: 3.523

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.